Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Alemtuzumab (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SUPPRESS
- 10 Oct 2019 Planned End Date changed from 1 May 2021 to 1 Dec 2020.
- 10 Oct 2018 Status changed from not yet recruiting to recruiting.
- 26 Oct 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.